Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis (NCT07202598) | Clinical Trial Compass
RecruitingPhase 2
Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis
United States10 participantsStarted 2025-11-12
Plain-language summary
Background:
Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), also known as Autoimmune polyendocrine syndrome type-1 (APS-1), is a disease that causes the immune system to attack parts of a person s body. In some people, APECED attacks the small intestine; this causes an illness called enteritis.
Objective:
To test a drug (emapalumab) in people with enteritis caused by APECED.
Eligibility:
People aged 2 to 75 years with APECED and enteritis. They must also be enrolled in protocol 11-I-0187.
Design:
Participants will have 10-13 study visits in an 18-month period.
Participants will be screened. They will have a physical exam with blood tests. These tests will be repeated at every study visit. They will have a test of their heart function. This will be at screening and prior to drug administration.
Other tests are optional: Participants may have imaging exams and a test of lung function. They may have an endoscopy, which is an exam of their digestive tract. Participants may provide samples of urine, stool, nail clippings, saliva, vaginal fluid, or skin. Photos may be taken of their skin or scalp. These tests may be repeated at some visits.
Emapalumab is given through a tube attached to a needle inserted into a vein. All participants will receive 7 doses: 2 on their first study visit; then 1 each at 30-day intervals. Some participants will have an observation period before they begin taking the drug; in those situations, they will either be seen in person or via video visit every 2 months before starting emapalumab to see how their symptoms change over time.
Participants will have a follow-up visit 1 month after their last dose. Then they will have 2 telehealth visits at 30-day intervals. They will have a final clinic visit 1 year after their first dose.
...
Who can participate
Age range2 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Participant must be able to understand and provide informed consent.
✓. Aged \>= 2 to \<= 75 years.
✓. Currently co-enrolled on NIH protocol 11-I-0187, "The Natural History and Pathogenesis of Human Fungal Infections."
✓. Patients with APECED (genetic or clinical diagnosis) and enteritis (with APECED ES \> 50 at screening).
✓. Duration of enteritis greater than 6 months.
✓. Is naive or unresponsive to other treatments for enteritis.
✓. Willingness to use acyclovir or valacyclovir prophylaxis for the prevention of herpes viral reactivation.
✓. Willingness to use entecavir prophylaxis against hepatitis B virus reactivation, if applicable.
Exclusion criteria
✕. Known history of hypersensitivity to emapalumab.
✕
What they're measuring
1
Averaged changes in APECED ES from baseline.
Timeframe: Duration of study
Trial details
NCT IDNCT07202598
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)